{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:56:35Z","timestamp":1775742995656,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Invasive pneumococcal disease (IPD) causes life-threatening illnesses including meningitis and bloodstream infection. Here, we report the impact of 7- and 13-valent pneumococcal conjugate vaccines (PCV7\/PCV13) after introduction into the Irish pediatric immunization schedule in 2008 and 2010, respectively, and the clinical details surrounding suspected PCV vaccine failures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Serotyping and antimicrobial susceptibility testing of all culture-confirmed cases referred from children &lt;16 years of age from July 2007 to June 2018 were assessed. Surveillance data were assessed to identify any potential vaccine failures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The number of IPD cases has decreased by &gt;50% since the introduction of PCVs. The most significant decline PCV serotypes in children &lt;2 years of age, with a 97% decline in PCV7 serotypes, incidence rate ratio (IRR) 0.03, 95% confidence interval (CI): 0.00\u20130.21; and a 78% decline PCV13-only (PCV13-7) serotypes, IRR 0.22, 95% CI: 0.05\u20131.04, respectively. However, there has been an increase in non-PCV13 serotypes in children &lt;2 years during the same period (IRR: 2.82, 95% CI: 1.02\u20137.84; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0463), with similar serotype trends observed for those 2\u20134 and 5\u201315 years of age. There were no clear vaccine replacement serotypes, instead a number of different serotypes emerged. Sixteen vaccine failures were identified, 10 of which were postbooster vaccine failures. Most failures were serotype 19A and resistant to antimicrobials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Further reducing the incidence of IPD is more challenging as the number of non-PCV13 serotypes has expanded and is now less susceptible to antimicrobials. Consequently, higher valency or broader target vaccines are now required to further prevent IPD in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002549","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T16:18:32Z","timestamp":1575908312000},"page":"339-344","source":"Crossref","is-referenced-by-count":18,"title":["Invasive Streptococcus pneumoniae Infections and Vaccine Failures in Children in Ireland From the Postvaccine Era From 2007 to 2018"],"prefix":"10.1097","volume":"39","author":[{"given":"Mary","family":"Corcoran","sequence":"first","affiliation":[{"name":"Irish Pneumococcal Reference Laboratory, Irish Meningitis and Sepsis Reference Laboratory, Children\u2019s Health Ireland at Temple Street, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolita","family":"Mereckiene","sequence":"additional","affiliation":[{"name":"Health Protection Surveillance Centre, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Cotter","sequence":"additional","affiliation":[{"name":"Health Protection Surveillance Centre, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Murchan","sequence":"additional","affiliation":[{"name":"Health Protection Surveillance Centre, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Cunney","sequence":"additional","affiliation":[{"name":"Irish Pneumococcal Reference Laboratory, Irish Meningitis and Sepsis Reference Laboratory, Children\u2019s Health Ireland at Temple Street, Dublin, Ireland"},{"name":"Department of Microbiology, Children\u2019s Health Ireland at Temple Street, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, the Royal College of Surgeons in Ireland, Dublin, Ireland"},{"name":"Department of Microbiology, Beaumont Hospital, Dublin, Ireland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"e1000348","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.","volume":"7","author":"Johnson","year":"2010","journal-title":"PLOS Med"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"8877","DOI":"10.1016\/j.vaccine.2011.09.075","article-title":"Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination.","volume":"29","author":"Hanage","year":"2011","journal-title":"Vaccine"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination.","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"e1005034","DOI":"10.1371\/journal.ppat.1005034","article-title":"Vaccination drives changes in metabolic and virulence profiles of Streptococcus pneumoniae.","volume":"11","author":"Watkins","year":"2015","journal-title":"PLoS Pathog"},{"key":"R5-20230912","first-page":"e000119","article-title":"Pre-vaccine serotype composition within a lineage signposts its serotype replacement - a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK.","volume":"3","author":"Gladstone","year":"2017","journal-title":"Microb Genom"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1017\/S0950268812000763","article-title":"Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England.","volume":"141","author":"Chapman","year":"2013","journal-title":"Epidemiol Infect"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2213-2600(17)30110-8","article-title":"Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.","volume":"5","author":"Savulescu","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thoraxjnl-2018-211767","article-title":"Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.","volume":"74","author":"Hanquet","year":"2019","journal-title":"Thorax"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","article-title":"Making sense of differences in pneumococcal serotype replacement.","volume":"19","author":"Lewnard","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1093\/ofid\/ofx162.158","article-title":"Direct and indirect impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD) among children and adults in the U.S.","volume":"4","author":"Pilishvili","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R15-20230912","article-title":"Amending decision 2002\/253\/EC laying down case definitions for reporting communicable diseases to the community network under decision No 2119\/98\/EC of the European Parliament and of the Council. section L159\/72.","year":"2008","journal-title":"Official Journal of the European Union"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S0950268810001743","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland.","volume":"139","author":"Vickers","year":"2011","journal-title":"Epidemiol Infect"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R20-20230912","first-page":"894","article-title":"Is it time to review the vaccination strategy to protect adults against invasive pneumococcal disease?","volume":"112","author":"Corcoran","year":"2019","journal-title":"Ir Med J"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1017\/S0950268817001194","article-title":"The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?","volume":"145","author":"Corcoran","year":"2017","journal-title":"Epidemiol Infect"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis.","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jinf.2018.06.004","article-title":"The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis.","volume":"77","author":"Balsells","year":"2018","journal-title":"J Infect"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.","volume":"36","author":"Greenberg","year":"2018","journal-title":"Vaccine"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"e0183191","DOI":"10.1371\/journal.pone.0183191","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.","volume":"12","author":"Dom\u00ednguez","year":"2017","journal-title":"PLoS One"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/eurpub\/ckw089","article-title":"Pneumococcal pneumonia vaccine breakthroughs and failures after 13-valent pneumococcal conjugated vaccine.","volume":"26","author":"Almeida","year":"2016","journal-title":"Eur J Public Health"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/INF.0000000000001041","article-title":"Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in catalonia, a region with low vaccination coverage.","volume":"35","author":"Moraga-Llop","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/INF.0b013e3181faa6be","article-title":"Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/cid\/cix418","article-title":"Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006-2014.","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"e0161257","DOI":"10.1371\/journal.pone.0161257","article-title":"Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany.","volume":"11","author":"van der Linden","year":"2016","journal-title":"PLoS One"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1542\/peds.2014-2426","article-title":"Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.","volume":"135","author":"Yildirim","year":"2015","journal-title":"Pediatrics"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0b013e318275614b","article-title":"Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.","volume":"32","author":"Kaplan","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1097\/INF.0000000000000818","article-title":"Pneumococcal meningitis vaccine breakthroughs and failures after routine 7-Valent and 13-Valent pneumococcal conjugate vaccination in children in France.","volume":"34","author":"Godot","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R35-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz221","article-title":"Changes in invasive pneumococcal disease spectrum after 13 valent pneumococcal conjugate vaccine implementation.","author":"Levy","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:33:54Z","timestamp":1694558034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002549","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}